AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Alkermes plc
Video analysis: ALKS
All videosNo video analysis for this stock yet. Request one from our team.
News: ALKS
Alkermes: A Slow-Burning Buy Prospect On Orexin-Agonist Promise
Alkermes plc is upgraded from Hold to Buy, driven by robust revenue growth, pipeline momentum, and strategic positioning in sleep and CNS disorders. Acquisition of Avadel and Lumryz launch propel >20% revenue growth in 2026; adjusted EBITDA guidance is $370–410M despite a GAAP net loss. Alixorexton's strong Phase 2 data in narcolepsy and IH, plus advancing orexin pipeline, underpin multi-billion-dollar long-term revenue potential.
Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards® program on Friday, Sept. 11, 2026. Now in its ninth year, this competitive grant program is designed to support the next generation of researchers working on the front lines to advance our understanding of diseases in the field of neuroscience. Building on prior award cycles, the program will continue to accept applications related to s.
Financial Review: C4 Therapeutics (NASDAQ:CCCC) and Alkermes (NASDAQ:ALKS)
Alkermes (NASDAQ: ALKS - Get Free Report) and C4 Therapeutics (NASDAQ: CCCC - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, analyst recommendations and institutional ownership. Insider and Institutional Ownership 95.2% of Alkermes shares are
Alkermes Chief Commercial Officer Sells 7,576 Shares for $373,000
The executive sold 7,576 shares. The transaction resulted in a 7% reduction in the insider's direct equity holdings.
Why Is Alkermes (ALKS) Up 1.7% Since Last Earnings Report?
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?
Alkermes (NASDAQ:ALKS) Stock Price Passes Above Two Hundred Day Moving Average – Here’s What Happened
Shares of Alkermes plc (NASDAQ: ALKS - Get Free Report) passed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $40.30 and traded as high as $49.35. Alkermes shares last traded at $49.16, with a volume of 660,776 shares. Wall Street Analysts Forecast Growth Several brokerages have
The Lancet Neurology Publishes Data From Alkermes' Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the publication of data from the Vibrance‑1 phase 2 study of alixorexton in adults with narcolepsy type 1 (NT1) in The Lancet Neurology. Alixorexton is a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of NT1, narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH). Based on the positive results demonstrated by alixorexton in the phase 2 Vibrance Studies in NT1 and NT2,.
Bank of America Corp DE Trims Position in Alkermes plc $ALKS
Bank of America Corp DE decreased its stake in shares of Alkermes plc (NASDAQ: ALKS) by 9.2% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,210,851 shares of the company's stock after selling 122,254 shares during the quarter. Bank
